Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Processa Pharmaceuticals Inc

PCSA ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: N/A

Last Close

$2.43

▼ -2.80%

Market Cap $8.15M · Vol 11.18K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$8.15M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

46.58

Momentum

Beta

0.99

vs Market

52W High

$14.00

82.64% below

52W Low

$1.75

38.86% above

Volume

11.18K

Avg 60.39K

P/B

1.33

Price-to-book

ROE

N/A

Return on equity

Free Float

87.65%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Processa Pharmaceuticals Inc (PCSA) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does PCSA pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-5.45%

+6.11%

-20.85%

+9.46%

YTD

-15.63%

-55.86%

-98.72%

-99.91%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-13,563,830.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-245.66% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	1.33
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	3.35M

Technical Indicators

50-Day SMA	$2.24
200-Day SMA	$3.46
RSI (14)	46.58
Beta	0.99
52-Week High	$14.00
52-Week Low	$1.75

Volume Today	11.18K
Avg Daily Volume (30D)	60.39K
Relative Volume	0.19x
Volatility (10D)	64.77
Volatility (30D)	157.52
Free Float	87.65%

Analyst Consensus

N/A

Current Price $2.43

Mean Target $25.00

52W Low$1.75 52W High$14.00

Current

Target

$1.75 $14.00

Current Analyst target

+928.81% upside potential · 0 analysts

Identifiers

ExchangeNasdaq

FIGIBBG003MN60F5

ISINUS74275C4033

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateAug 7, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapy (NGC) small molecules. The three NGC treatments in its pipeline are NGC-Capecitabine (NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem) and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri) and two non-oncology drug assets are PCS12852, and PCS499. NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil.PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine. PCS11T is a prodrug of the active metabolite of irinotecan (SN-38). PCS12852 is a specific and potent 5HT4 agonist that is in Phase IIB and is a potential treatment for diabetic gastroparesis patients. PCS499 is a drug that can be used to treat unmet medical needs and conditions caused by multiple pathophysiological changes.